Edema Clinical Trials Market Report 2025

The edema clinical trials market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.23 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period is attributed to the increasing prevalence of edema conditions, rising burden of chronic diseases, growing healthcare awareness and diagnosis, expansion of healthcare infrastructure, increasing geriatric population, and higher public and private funding.

The edema clinical trials market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period is driven by rising demand for personalized medicine, increased focus on patient recruitment diversity, growth of decentralized and virtual clinical trials, expansion of government support programs, and higher investment from global pharmaceutical companies. Key trends in the forecast period include technological advancements in remote monitoring, innovation in digital biomarkers, development of artificial intelligence analytics, progress in three-dimensional imaging, research in personalized therapies, and integration of telemedicine into clinical trials.

The growing incidence of lifestyle-related diseases is expected to contribute significantly to the expansion of the edema clinical trials market. These diseases develop as a result of daily habits and behaviors, including physical inactivity, poor nutrition, and substance use. The rise in such conditions is primarily due to unhealthy dietary patterns, with the widespread consumption of processed and high-calorie foods leading to obesity, diabetes, and cardiovascular complications. Edema clinical trials play a key role in addressing these diseases by developing and evaluating treatments for fluid retention commonly associated with these chronic health issues. For example, in March 2024, the Office for Health Improvement and Disparities, a government department in the United Kingdom, reported that from March 2022 to March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by twenty-two percent, and for those with type 2 diabetes, the increase was twenty-one percent. Additionally, the percentage of individuals achieving target HbA1c levels rose to thirty-seven point nine percent, the highest ever recorded by the National Diabetes Audit. As a result, the growing prevalence of lifestyle-related diseases is supporting the growth of the edema clinical trials market.

Companies involved in the edema clinical trials market are prioritizing the development of advanced solutions such as refillable eye implants to enhance treatment effectiveness and patient adherence for managing chronic edema-related eye disorders. A refillable ocular implant is a medical device placed in the eye that delivers medication continuously over time and can be refilled without removal or replacement, making it a long-term treatment option for chronic conditions such as macular edema. For example, in February 2025, Roche Holding AG, a pharmaceutical company based in Switzerland, received approval from the United States Food and Drug Administration for Susvimo, the first and only continuous medication delivery system for diabetic macular edema and diabetic retinopathy. These are leading causes of vision loss in individuals with diabetes. Susvimo provides an alternative to frequent eye injections by significantly reducing the number of treatments required annually. This innovation represents a major step forward in eye care by improving treatment adherence and lowering the burden on patients, which may lead to better long-term outcomes for those affected by these chronic eye conditions.

In September 2025, Alcon Inc., an eye care device company based in Switzerland, acquired LumiThera Inc. for an undisclosed amount. Through this acquisition, Alcon aims to expand the availability of LumiThera’s Valeda photobiomodulation device, which is used for the treatment of early and intermediate stages of dry age-related macular degeneration. This move enhances Alcon’s retinal treatment offerings by adding clinic-based, noninvasive therapies designed to help a large number of patients improve their vision. LumiThera Inc. is a medical device company based in the United States that conducts edema clinical trials.

Major players in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG.

North America was the largest region in the edema clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in edema clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the edema clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Edema clinical trials are studies conducted to assess the safety, effectiveness, and potential treatments for edema, which is the abnormal accumulation of fluid in body tissues. These trials evaluate drugs, medical devices, or therapeutic interventions aimed at reducing swelling, improving fluid balance, or addressing underlying conditions such as heart, kidney, or liver disorders.

The primary phase types of edema clinical trials are Phase I, Phase II, Phase III, and Phase IV. Phase I trials represent the initial stage of clinical research, focusing on evaluating the safety, tolerability, and optimal dosage of a new therapy in a small group of participants. These trials cover various types of edema, including peripheral edema, pulmonary edema, cerebral edema, and nephrotic syndrome edema. Study designs include interventional, observational, and expanded access trials. Participants include pediatric, adult, and geriatric populations, and key end-users consist of pharmaceutical companies, research institutions, contract research organizations (CROs), and academic research centers.

The edema clinical trials market research report is one of a series of new reports that provides edema clinical trials market statistics, including edema clinical trials industry global market size, regional shares, competitors with an edema clinical trials market share, detailed edema clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the edema clinical trials industry. This edema clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The edema clinical trials market includes revenues earned by entities by providing services such as patient recruitment and screening, safety and adverse event reporting, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.